Talk:Ibritumomab tiuxetan

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ibritumomab tiuxetan.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Clean![edit]

I have now fixed the grammar mistakes and cleaned this article. I have also put it in the correct category. (72.136.49.4 00:22, 28 December 2005 (UTC))[reply]

Thank you!!! TestPilot 14:11, 28 December 2005 (UTC)[reply]

Pronunciation[edit]

I think it is pronounced EYE-bri-TOOM-oh-mab, not IH-bri-TOOM-oh-mab. Regards, Blake3522 11:45, 20 July 2007 (UTC)[reply]

I've worked on the drug at Biogen Idec for 5+ years, and I've never heard anyone call it anything but IH-bri-TOOM-oh-mab, defined as the mouse antibody without the chelator, tiuxetan. Ibritumomab tixuetan is the antibody+chelator, and when it has an isotope bound to the chelator it becomes either ¹¹¹In-ibritumomab tixuetan or ⁹⁰Y-ibritumomab tixuetan. (Or you can just do what we do, and call it all Zevalin.)Wsaville (talk) 18:11, 16 January 2008 (UTC)[reply]

Circular Link[edit]

Hi. I've removed the link to ibritumomab, which merely redirects back to this very page. The pronunciation is from an AOL site, I hope that's okay. I asssume they have (or had) the money to do it right, all else about AOL aside. Kenmcl2 15:20, 27 July 2007 (UTC)[reply]

two different drugs[edit]

Hi.

In-111 Zevalin and Y-90 Zevalin are two different drugs. The terms "Zevalin" or "Ibritumomab tiuxetan" by themselves do not precisely refer to RIT. They are the cold antibody without the radioactive molecule attached.

Since yttrium emits pure beta radiation, it cannot be used to get a picture with a gamma camera. So the indium version is used instead for the pretreatment image (taken about one week before the tx day). Indium emits some gamma along with beta.

The image is taken to make sure that the drug will go to where it should, and not go to where it shouldn't (e.g., excess amounts to marrow, liver, etc)

Kenmcl2 15:47, 27 July 2007 (UTC)[reply]

same point, so the formula C6382H9830N1672O1979S5499Y111In is wrong, its either Y-90 or In-111 so the MW is also probably wrong.--128.231.88.4 (talk) 21:36, 27 January 2009 (UTC)[reply]

"Zevalin®" listed at Redirects for discussion[edit]

An editor has identified a potential problem with the redirect Zevalin® and has thus listed it for discussion. This discussion will occur at Wikipedia:Redirects for discussion/Log/2022 April 15#Zevalin® until a consensus is reached, and readers of this page are welcome to contribute to the discussion. BD2412 T 05:00, 15 April 2022 (UTC)[reply]